You will be now forwarded to the Fresenius Career page.

If the automatic redirect is not working, please click on the following link.

Fresenius Career

Fresenius Kabi has agreed to collaborate with Phlow Corporation, a public benefit company, to expand access to affordable sterile injectables formulated for U.S. children’s hospitals and to help strengthen the supply chain for U.S.-sourced API and essential medicines. The companies will work together to supply private-labelled products, co-develop and manufacture novel products and make essential medicines rapidly available in the event of a public health emergency.

Fresenius Kabi has agreed to collaborate with Phlow Corporation, a public benefit company, to expand access to affordable sterile injectables formulated for U.S. children’s hospitals and to help strengthen the supply chain for U.S.-sourced API and essential medicines. The companies will work together to supply private-labelled products, co-develop and manufacture novel products and make essential medicines rapidly available in the event of a public health emergency.

Contact

Director Investor Relations
T: +49 (0) 6172 608-2486
elisabeth.truckenbrodt@fresenius.com

Share Price

FRESENIUS SE & CO. KGaA

 

 

 

Data is delayed by 15 minutes.

Share Price Information

Related Links

Interactive Tool

Library

General Credit Presentation (PDF, 1.73 MB)

Ensure financial flexibility, maintain our investment grade rating, limit refinancing risks and optimize the cost of capital are the main objectives in Fresenius’s financing strategy.

To remain financially flexible, we maintain adequate liquidity headroom. We are committed to our investment grade rating, which provides us with advantages with respect to market access and funding costs.

Our refinancing risks are limited due to a balanced maturity profile that is characterized by a broad range of maturities with a high proportion of mid- and long-term debt up to 2034. Relevant financing instruments include bonds, Schuldschein Loans and bank loans. In addition, Fresenius maintains a commercial paper program. 

Another key objective of Fresenius’ financing strategy is to optimize the cost of capital by employing an adequate mix of equity and debt.

In 2025, deleveraging will remain a key priority. Fresenius has upgraded its leverage target corridor to 2.5 to 3.0x net debt/EBITDA (previously 3.5 to 3.0x). This allows us to stay financially flexible while solidifying our solid investment grade rating.
 

Fresenius Group

¹ Prior-year figures have been adjusted due to the deconsolidation of Fresenius Medical Care operations

² Before special items

³ At average exchange rates for both net debt and EBITDA; pro forma closed acquisitions/divestitures, including lease liabilities, including Fresenius Medical Care dividend; Net debt adjusted for the valuation effect of the exchangeable bond

Fresenius Helios is one of the largest and most medically-advanced operators of both in- and outpatient care in Europe, offering expertise in all areas of clinical care. 

Fresenius Helios owns and operates Helios hospitals in Germany and Quirónsalud hospitals in Spain and Latin America. Every year more than 24 million patients choose Helios for medical treatment, of whom 22.2 million are outpatients. Fresenius Helios is committed to the highest quality clinical and nursing care.

Helios

Based in Berlin, Helios owns and operates 87 clinics, including seven maximum care hospitals in Erfurt, Berlin-Buch, Duisburg, Wuppertal, Schwerin, Krefeld and Wiesbaden. Helios hospitals provide inpatient care to about 1.2 million patients annually.

Quironsalud

Quirónsalud operates 57 hospitals, 100 outpatient centers and around 300 occupational risk prevention centers. Active in every major metropolitan region of Spain, and now with seven hospitals in Latin America, Madrid-based Quirónsalud has more than 49,000 employees.

 

360° Panorama laden

Panorama wird geladen....

Extreme concentration and the most modern medical technology: Here you can take a look around the operating room as Peter Horn, M.D., PhD, Head of Neurosurgery at Helios Hospital Dr. Horst Schmidt Kliniken, successfully removes a 4-centimeter (1.6-inch) tumor from a patient’s brain.

Management Board

Supervisory Board

Corporate Governance

Compliance

Contact

T: +49 (0) 6172 608-4030
leif.heussen@fresenius.com

Documents

Text as PDF document (PDF, 110 KB)

Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has donated 250,000 euros to UNICEF, the United Nations Children's Fund, to mark the company’s 25th anniversary. UNICEF will use the donation to support the COVAX vaccination initiative to fight the COVID-19 pandemic in about 140 countries. UNICEF delivers COVID-19 vaccines and other equipment around the world. With 250,000 euros UNICEF is able, for example, to protect almost 70,000 teachers or medical personnel from a COVID-19 infection. With every health worker who is protected from the virus the care of numerous children can be ensured. With every vaccinated teacher, more and more children can return to school.

Rice Powell, CEO of Fresenius Medical Care, presented a symbolic check at a virtual ceremony. “As a company in the healthcare branch, we bear a special responsibility to our patients, to our employees and as a member of our society as well,” he said. “In this anniversary year, we must do everything to defeat the global corona pandemic. We are doing this by various means. Our donation to UNICEF is targeted to protect the health of children in less developed and in developing countries. This lives up to our values and our mission for the past 25 years to maintain life and improve the quality of life.”

As the world’s largest single buyer of vaccines, UNICEF has unique experience, gained over many years, in purchasing and delivering goods to children in need. Working on behalf of nearly 100 countries, UNICEF procures more than 2 billion vaccine doses for routine vaccinations and outbreaks of diseases every year. Over the past 20 years, the organization helped provide more than 760 million children with life-saving vaccines.

Christian Schneider, Executive Director of UNICEF Germany said: “The impact of the COVID-19 pandemic threatens children around the world. Their access to health facilities is compromised, many still cannot go to school. Also, violence against children is increasing. The COVAX vaccine initiative plays a decisive role in fighting the pandemic and reducing its consequences, especially in the lower-income regions of the world. The pandemic is not over for anyone until it is over for everyone. To that end, UNICEF provides its unique and longstanding expertise in vaccine procurement and logistics. But we cannot meet this challenge alone. We therefore thank Fresenius Medical Care for their generous support.”

COVAX is a global initiative in which the vaccination alliance Gavi, the World Health Organization (WHO), UNICEF and the Coalition for Epidemic Preparedness Innovations (CEPI) are working together to facilitate the equitable global distribution of COVID-19 vaccines.

From the beginning of the COVID-19 pandemic, Fresenius Medical Care has been intensely engaged on a variety of fronts. In addition to sweeping measures to protect against infection and to ensure continuous operation of our dialysis centers, the company opened its facilities in several countries to allow vaccination of patients and, in some cases, the general public.

123